Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 14, 2014; 20(30): 10223-10237
Published online Aug 14, 2014. doi: 10.3748/wjg.v20.i30.10223
Published online Aug 14, 2014. doi: 10.3748/wjg.v20.i30.10223
Table 7 Randomized controlled trial comparing radiofrequency ablation to percutaneous ethanol injection for the treatment of early stage hepatocellular carcinoma
| Ref. | No. of patients | Initial response | Failure | 3 yr survival | P value |
| Lencioni et al[128] 2003 | RFA (52) | 91% | 8% | 81% | NS |
| PEI (50) | 82% | 34% | 73% | ||
| Lin et al[129] 2004 | RFA (52) | 96% | 17% | 74% | 0.014 |
| 88% | |||||
| PEI (52) | 88% | 45% | 50% | ||
| Shiina et al[122] 2005 | RFA (118) | 100% | 2% | 80% | 0.020 |
| PEI (114) | 100% | 11% | 63% | ||
| Lin et al[130] 2005 | RFA (62) | 97% | 16% | 74% | 0.031 |
| PEI (62) | 89% | 42% | 51% | ||
| Brunello et al[131] 2008 | RFA (70) | 96% | 34% | 59% | NS |
| PEI (69) | 66% | 64% | 57% |
- Citation: Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol 2014; 20(30): 10223-10237
- URL: https://www.wjgnet.com/1007-9327/full/v20/i30/10223.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i30.10223